The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*

Zhao, Yan; Wu, Liming; Lu, Qianjin; Gao, Xing‐Hua; Zhu, Xiaohong; Yao, Xu; Li, Linfeng; Li, Wei; Ding, Yangfeng; Song, Zhiqiang; Liu, Luyao; Dang, Ningning; Zhang, C; Liu, Xueying; Gu, Jie; Wang, J.; Geng, Songmei; Liu, Q.; Guo, Yong; Dong, Li; Su, Huichun; Bai, Lang; T. O’Malley, John; Luo, Jianfeng; Laws, Elizabeth; Mannent, Leda; Ruddy, M.; Amin, Nikhil; Bansal, Ashish; Ota, Tomoko; Wang, Ming-Yun; Zhang, J

doi:10.1111/bjd.20690

Public

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*

Published in British Journal of Dermatology • Aug 6, 2021

Authors:

Yan Zhao

Liming Wu

Qianjin Lu

Abstract

BACKGROUND: Dupilumab is an antibody against interleukin-4 receptor α, used in the treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate-to-severe AD. METHODS: In this randomized, double-blind, placebo-controlled, pa...

Subject

Dupilumab

Atopic dermatitis

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!